Human Epidermal Growth Factor Receptor 2 Expression in Prostatic Carcinomas: A Systematic Review and Meta‐Analysis of a Potential Therapeutic Target

INTRODUCTION: The clinical relevance of HER2 expression profile in solid cancers has expanded with the evolving landscape of HER2 targeting agents. This systematic review and meta-analysis aim to detail the prevalence of HER (over)expression in prostate cancer and identify patient/disease subgroups with enriched HER2 overexpression. METHODS: index, and LFK index. RESULTS: was 91.63% with meta-regression analysis showing study quality as a source of heterogeneity (p = 0.043). LFK index was 1.93 (moderate publication bias risk, p = 0.054). CONCLUSIONS: HER2 overexpression is rare in prostatic carcinomas but nearly half show HER2 expression of Score 1 or above. Cases with higher Gleason score and advanced disease stage are more likely to overexpress HER2.